Barclays analyst Gena Wang lowered the firm’s price target on 4D Molecular (FDMT) to $38 from $45 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular Therapeutics Reports Increased Quarterly Loss
- 4D Molecular reports Q1 EPS (86c), consensus (86c)
- 4D Molecular reports Q1 EPS (86c), consensus (83c)
- 4D Molecular sees cash, equivalents funding planned operations into 2028
- 4D Molecular announces RMAT designation granted by FDA for 4D-150 for DME
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue